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ARTICLE
Cancer risk in patients with Noonan syndrome carrying
a PTPN11 mutation
Marjolijn CJ Jongmans*,1, Ineke van der Burgt1, Peter M Hoogerbrugge2, Kees Noordam3, Helger G Yntema1,
Willy M Nillesen1, Roland P Kuiper1, Marjolijn JL Ligtenberg1, Ad Geurts van Kessel1, J Han JM van Krieken4,
Lambertus ALM Kiemeney5,6 and Nicoline Hoogerbrugge1
Noonan syndrome (NS) is characterized by short stature, facial dysmorphisms and congenital heart defects. PTPN11 mutations
are the most common cause of NS. Patients with NS have a predisposition for leukemia and certain solid tumors. Data on the
incidence of malignancies in NS are lacking. Our objective was to estimate the cancer risk and spectrum in patients with NS
carrying a PTPN11 mutation. In addition, we have investigated whether specific PTPN11 mutations result in an increased
malignancy risk. We have performed a cohort study among 297 Dutch NS patients with a PTPN11 mutation (mean age 18
years). The cancer histories were collected from the referral forms for DNA diagnostics, and by consulting the Dutch national
registry of pathology and the Netherlands Cancer Registry. The reported frequencies of cancer among NS patients were
compared with the expected frequencies using population-based incidence rates. In total, 12 patients with NS developed a
malignancy, providing a cumulative risk for developing cancer of 23% (95% confidence interval (CI), 8–38%) up to age 55
years, which represents a 3.5-fold (95% CI, 2.0–5.9) increased risk compared with that in the general population.
Hematological malignancies occurred most frequently. Two malignancies, not previously observed in NS, were found: a
malignant mastocytosis and malignant epithelioid angiosarcoma. No correlation was found between specific PTPN11 mutations
and cancer occurrence. In conclusion, this study provides first evidence of an increased risk of cancer in patients with NS and a
PTPN11 mutation, compared with that in the general population. Our data do not warrant specific cancer surveillance.
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INTRODUCTION
Noonan syndrome (NS, OMIM 163950) is an autosomal dominant
developmental disorder characterized by short stature, facial dysmorph-
isms and congenital heart defects (reviewed in Tartaglia et al1). It is a
relatively common syndrome with an estimated incidence of 1 in 2500
births. NS is associated with a higher risk for benign and malignant
proliferative disorders. Approximately 10% of the children with NS
are affected by a mild myeloproliferative disorder, which is usually
self-limiting.2 A smaller percentage of patients develops juvenile mye-
lomonocytic leukemia (JMML)3,4 and/or other hematological malig-
nancies.5–11 In addition, several case reports have suggested a possible
increased incidence of solid tumors in NS patients, specifically neuro-
blastoma and embryonal rhabdomyosarcoma.12–19 Benign proliferative
conditions reported include multiple giant cell lesions and granular cell
tumors.20,21 Until now, heterozygous germline mutations in six genes
encoding components of the RAS/MAPK pathway, that is, PTPN11,
KRAS, SOS1, RAF1, NRAS and SHOC2 have been identified in NS.1
The RAS/MAPK pathway represents a signal transduction cascade
involved in processes of cell proliferation, differentiation, survival and
death. Mutations in PTPN11, which encodes the non-receptor protein
tyrosine phosphatase SHP-2, are most frequently observed and account
for B50% of NS cases. SHP-2 has two Src homology 2 domains
(N-SH2 and C-SH2), a catalytic protein tyrosine phosphatase (PTP)
domain and a COOH terminus containing tyrosine phosphorylation
sites. Most PTPN11 mutations involved in NS disrupt the autoinhibi-
tory interaction between the N-SH2 and the PTP domain, resulting in
enhanced phosphatase activity and increased signaling through the
RAS–MAPK pathway.22
The observed increase in JMML incidence in NS and the important
role of SHP-2 in RAS signaling, suggest a role of mutant SHP-2 in
cancer development. Indeed, somatic mutations in PTPN11 occur in
B35% of sporadic JMML and in a small percentage of other
hematological malignancies.23–25 Similarly, solid tumors have been
screened for somatic PTPN11 mutations. In some of them, such as
lung-, liver- and colorectal cancer, PTPN11 mutations have been
identified, be it infrequent.19,26 On the basis of these findings, and
considering the universal role of increased RAS–MAPK signaling in
oncogenesis, we hypothesized that patients with NS might have an
increased risk for developing a broad range of malignancies, in
addition to leukemia. So far, no quantitative data are available on
the risk of cancer in NS caused by PTPN11 mutations. Therefore,
guidelines for cancer prevention in patients with NS are yet to be
developed. We have performed a first cohort study to explore the
cumulative risk of developing cancer in patients with NS carrying a
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germline PTPN11 mutation. In addition, we investigated whether
specific PTPN11 mutations result in an increased cancer risk and
whether specific malignancies are particularly associated with NS. For
the latter purpose, we have reviewed all NS patients with a PTPN11
mutation and a malignancy reported in the literature.
PATIENTS AND METHODS
Study population
The study population consisted of 318 Dutch patients with NS in whom a
germline PTPN11 mutation was identified in the laboratory for DNA diag-
nostics of the Department of Human Genetics, Radboud University Nijmegen
Medical Center, the Netherlands. To obtain a genetically uniform cohort of
patients, we exclusively included patients with a PTPN11 mutation. This gene is
most commonly involved in NS, accounting for B50% of patients. The
mutations were identified between January 2002 and December 2008. Patients
with a mutation related to LEOPARD syndrome (n¼17) and patients who died
prenatally or in the first 3 months of life (n¼4) were excluded. After this
exclusion, the cohort consisted of 235 index patients and 62 affected family
members, of which 143 (48%) were males and 154 (52%) were females. At the
end of the follow-up period, the patients had a mean age of 18 years and a
median age of 13 years (range 0.6–95 years).
Cancer follow-up
Diagnoses of cancer were retrieved using three different sources of information.
First, we screened the medical history of the patients using the referral forms
for PTPN11 analysis. Next, we performed a search in the National Automated
Archive of Pathology (PALGA). All histology and cytology reports in the
Netherlands are collected in this national database, which was founded in 1971
and achieved virtually complete national coverage in 1980.27 As PALGA is an
incomplete database for hematological malignancies and lacks malignancies
without histological confirmation, we also consulted The Netherlands Cancer
Registry (NCR). The NCR has a complete national coverage since 1989.
Statistical methods
Time at risk started on date of birth of the patient and ended on the date of cancer
diagnosis, emigration, the date of death or the closing date of the study (5
December 2008), whichever occurred first. Cumulative risks of cancer were
calculated by standard Kaplan–Meier analysis in which the end point was defined
as a diagnosis of any cancer and follow-up was defined as age at diagnosis. Patients
who died before a cancer diagnosis, were lost to follow-up or reached the end of the
study period without a cancer diagnosis, were censored at the corresponding age.
To be able to compare the observed cumulative risk of cancer among the
study population with the average cumulative risk in the Dutch population, we
calculated the expected frequency of cancer in the study population based on
the Dutch population-based incidence rates in 2002–2006 http://www.
ikcnet.nl). Because the Netherlands has a nationwide population-based cancer
registry, reference values can be taken efficiently from the registry and can be
considered more valid and stable than estimates taken from a specific (smaller)
control group. Basal cell carcinoma of the skin was excluded from the analysis,
as this neoplasm is not registered in the NCR. For the calculation of the
expected frequency, we multiplied the gender and 5-year age-specific popula-
tion years in the study population with the gender and 5-year age-specific
incidence rates in the Dutch population. Subsequently, the 95% confidence
intervals (CIs) of the observed versus expected ratios were calculated using the
open source program OpenEpi version 2.3 (http://www.openepi.com).
Sequence analyses
Sequencing of PTPN11 exons 1–4, 7, 8 and 11–14 and surrounding splice
donor and acceptor sites was performed in a routine DNA diagnostic setting
(www.dnadiagnostieknijmegen.nl) on DNA isolated from peripheral blood
cells. Primer sequences and PCR conditions are available upon request. In
one patient who was diagnosed with acute lymphocytic leukemia (ALL),
mutation analysis was repeated on DNA isolated from gastric antrum tissue,
to confirm the germline status of the mutation.
Except for one JMML and one malignant mastocytosis, all malignancies
were available for sequence analysis. In the patient with ALL, DNA was
extracted from bone marrow cells, in all other cases DNA was extracted from
paraffin-embedded tumor tissue. The sample derived from the patient with
basal cell carcinoma, had a tumor cell percentage of less than 60% and was,
therefore, excluded from further analysis.
Primer pairs were developed that covered a region of approximately 150 base
pairs, including the PTPN11 mutation identified in the germline of the patient.
Primer sequences and PCR conditions are available upon request.
RESULTS
The median follow-up time for cancer in our cohort of 235 index
patients and 62 affected family members was 13 years (range 0.6–95
years). Approximately 18.5% of the patients were followed for less
than 5 years, 36.4% for 5–15 years and 45.1% for more than 15 years.
In total, 12 malignancies were observed: three in children (r15 years),
three in adolescents and young adults (15–29 years) and six in adults
(Z30 years) (Table 1). The median age at diagnosis was 25 years
(range: 0–57). One patient developed a basal cell carcinoma that was
not included in our statistical analyses. In one case, the definitive
cancer diagnosis was unclear and, as a consequence, this patient was
censored at the date of that arbitrary diagnosis. This latter patient, a
5-year-old child, carried a c.188A4G (p.Tyr63Cys) PTPN11 mutation
and was diagnosed with nephroblastomatosis and, possibly, a small
nephroblastoma. The germline status of the c.188A4G mutation in
the patient with ALL was confirmed through the analysis of DNA
isolated from previously obtained stomach (gastric antrum) tissue
from this patient. Out of 10, 5 PTPN11 mutations found in our NS
patients with a malignancy were previously reported as somatic
mutations in sporadic malignancies (Table 2). The frequency of
malignancies among carriers of the same germline mutation in our
cohort is also displayed in Table 2.
Assessment of the occurrence of cancer in our study cohort
(Figure 1) provided a cumulative risk of 23% (95% CI, 8–38%) up
to the age of 55 years, which represents a 3.5-fold increased risk (95%
CI, 2.0–5.9) compared with that in the general population.
Breast cancer was observed twice, whereas all other malignancies
were observed only once. Six cancer types have previously been
reported in the literature in patients with NS and a PTPN11 mutation,
that is, JMML, neuroblastoma, ALL, non-Hodgkin lymphoma, glioma
and breast cancer (Table 1).
The child with JMML harbored a de novo p.Gly503Ala mutation. To
our knowledge, this mutation has not yet been reported as a germline
mutation in a patient with NS, but only as a somatic event in
JMML.23,24,28,29 Other tissues of this patient were unavailable to
confirm the germline status of the mutation. However, the child was
reported to have a valvular pulmonic stenosis, an atrial septum defect,
hypertelorism and low-set ears with a thick helix, and, therefore, likely
had NS. Photographs of the patient were seen by Dr I van der Burgt
(coauthor), and she considered the patient’s facial features as
suggestive for NS. It can be difficult to distinguish a benign myelo-
proliferative disorder, which is usually self-limiting and frequently
observed in NS, from the rare aggressive condition JMML.28,30,31
Assessment of the clonal status of the monocytic population can be
helpful in this respect,32 but we were unable to infer whether such a
diagnostic test was performed in this patient. The patient underwent a
bone marrow transplantation, indicating that the course of the disease
was aggressive.
In a search for copy number alterations of PTPN11 mutant alleles,
we performed sequence analysis in tumor DNA of 9 out of 12 patients
diagnosed with a malignancy. None of the sequences showed
an overrepresentation of the mutated allele compared with the wild-
type allele.
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DISCUSSION
Our cohort study shows a 3.5-fold (95% CI, 2.0–5.9) increase in the
overall cancer risk up to the age of 55 years in NS patients with a
PTPN11 mutation, compared with that in the general population. We
encountered six patients who developed cancer at adult age, whereas
until now only four adult patients with a germline PTPN11 mutation
and a malignancy have been reported in the literature. The overall risk
of cancer up to the age of 70 years cannot be estimated because of the
age distribution in our cohort, with a majority of patients below 30
years of age.
As expected, hematological malignancies were most frequent (4/12,
33%). In one patient, this malignancy was specified to be a malignant
mastocytosis, which so far has not been reported in NS. The non-
hematological malignancies observed included three novel cancers in
NS: a malignant epithelioid angiosarcoma, a colon cancer of the
sigmoid and a basal cell carcinoma.
One way to explore potential correlations between germline
PTPN11 mutations and the development of a specific malignancy is
screening for loss of heterozygosity and/or uniparental disomy, in
conjunction with duplication or amplification of a heterozygous
germline PTPN11 mutation in the tumors of patients. This two-hit
scenario was previously observed in NS, but is not a consistent finding
in all NS-associated malignancies.7,40 In our cohort, we did not
observe multiple copies of the mutant PTPN11 allele in nine tumors
tested. As a consequence, we can only speculate about the influence of
PTPN11 mutations on the development of these malignancies. For
instance, we found one patient with colorectal cancer diagnosed at an
unusually young age of 44 years. This early onset may be related to the
PTPN11 mutation. In sporadic colorectal cancer an association has
been found with the RAS–MAPK pathway and activating mutations in
the KRAS oncogene are known to have a role in the progression from
a benign adenoma to a dysplastic adenocarcinoma.41 Nearly 50% of
colon cancers harbor activating mutations in KRAS.41 Therefore, the
germline PTPN11 mutation in the patient with colorectal cancer may
have played a role in tumor progression.
Similarly, a relation between PTPN11 and breast cancer has not
been noted before. Remarkably, however, two patients in our cohort
(48 and 52 years of age) developed breast cancer, which has a mean
age at diagnosis of 60 years in the general population. Interestingly,
several studies have shown a role for RAS–MAPK pathway activation
in breast cancer development.42 Furthermore, women with Neurofi-
bromatosis type1, another syndrome associated with aberrant RAS
Table 1 Patients with Noonan syndrome carrying a germline PTPN11 mutation and diagnosed with a malignancy reported here (1–12) and
from the literature
No./Ref. Malignancy Age at diagnosis PTPN11 mutation
1 JMML 1 year c.1508G4C (p.Gly503Ala)
2 Neuroblastoma (adrenal gland) 1 year c.844A4G (p.Ile282Val)
Mutesa et al18 Neuroblastoma 5 months c.179G4C (p.Gly60Ala)
Bentires-Alj et al19 Neuroblastoma ? c.185A4C (p.Tyr62Cys)
Kondoh et al16 Neuroblastoma 6 months c.1504T4A (p.Ser502Thr)
Chantrain et al5 Neuroblastomaa 4 years c.922A4G (p.Asn308Asp)
3 Dysembryoplastic neuro-epithelial tumor (temporal lobe) 10 years c.179G4C (p.Gly60Ala)
4 Oligodendroglioma (hypothalamus)b 17 years c.417G4C (p.Glu139Asp)
Sherman et al33 Low grade glioneural tumor 6 years c.172A4G (p.Asn58Asp)
Martinelli et al34 Oligodendrogliomac 24 years c. 64A4G (p.Thr22Ala)
Schuettpelz et al35 Pilocytic astrocytoma 8 years c.1471_1472delinsTT (p.Pro491Phe)
5 Precursor B-ALL 23 years c.188A4G (p.Tyr63Cys)
Roti et al11 Common B ALL 17 years c.179G4C (p.Gly60Ala)
Karow et al7 Pre-B cell ALL 2 years c.1510A4G (p.Met504Val)
Karow et al7 Pre-B cell ALL 8 years c.417G4C (p.Glu139Asp)
Chantrain et al5 AML-M4a 5 years c.922A4G (p.Asn308Asp)
La Starza et al8 AML-M4 34 years c.178G4T (p.Gly60Cys)
Matsubara et al10 CMML 35 years c.922A4G (p.Asn308Asp)
6 Non-Hodgkin lymphoma (jejunum) 25 years c.1472C4T (p.Pro491Leu)
Ferrero et al6 Non-Hodgkin lymphomad ? c.1508G4A (p.Gly503Glu)
Lo et al9 Hodgkin’s lymphoma 35 years c.1507G4C (p.Gly503Arg)
7 Multifocal ductal breast cancer 48 years c.774G4T (p.Glu258Asp)
8 Ductal breast cancer 52 years c.925A4G (p.Ile309Val)
Shaw et al36 Breast cancere 45 years c.317A4C (p.Asp106Ala)
9 Malignant epithelioid angiosarcoma (mediastinum) 38 years c.1510A4G (p.Met504Val)
10 Colorectal cancer (sigmoid) 44 years c.1510A4G (p.Met504Val)
11 Malignant mastocytosis 46 years c.922A4G (p.Asn308Asp)
12 Basal cell carcinoma 57 years c.188A4G (p.Tyr63Cys)
Yoshida et al37 Hepatoblastoma 1 months c.922A4G (p.Asn308Asp)
The lines in white are patients from our study cohort, the lines in gray are patients reported in the literature. Reports of children with NS who developed JMML are not included, these are
summarized in the report of Aoki et al.38
aSame patient.
bThis patient has previously been published by us.39
cThe p.Thr22Ala change was found in a brain tumor and subsequently in peripheral blood cells. The patient had no features of NS. This molecular lesion results in an increased basal phosphatase
activity of PTPN11 and was not observed in over 300 control individuals.34
dThe mutation was identified in the son of this patient. The mother had short stature and a facial appearance typical of NS. DNA was not available for segregation analysis.
eMutation details derived by personal communication with the author.
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signaling, are at a moderately increased risk of developing breast
cancer.43 However, in a large panel of human breast cancers, no
somatic mutations in PTPN11 were detected.19
It is known that somatic PTPN11 mutations associated with cancer
generally confer a higher activation of SHP-2 function than those
associated with NS. Likewise, SHP-2 mutants related to NS-associated
leukemia exhibit higher PTP activity than do those related to NS
alone.22,29,44 On the basis of these findings we hypothesized that the
PTPN11 mutations found in our cohort of NS patients with a
malignancy might show overlap with mutations detected somatically
in cancer. Indeed, half of the NS patients with cancer are carriers of a
mutation that has previously been reported as a somatic mutation in
sporadic malignancies (Table 2).38 However, also 34% of the NS
patients without cancer diagnosis in our cohort carried a mutation
that has previously been detected somatically in cancer. These data
suggest that assessment of the cancer risk based on the type of
mutation detected is not feasible.
Remarkably, the p.Gly503Ala change identified in a patient with NS
and JMML, has so far only been observed as a somatic mutation in
JMML. For such mutations, which only seem to have a role as an
acquired anomaly in leukemia, an association with embryonic lethality
has been suggested.24 A mosaicism for the p.Gly503Ala mutation
could explain our finding of this aberration in a life-born child.
Unfortunately, no other tissues of this patient were available for
further analysis.
As 65 (22%) of the patients in the study cohort were born before
PALGA and NCR had an almost complete coverage in the
Netherlands, relevant data may be lacking for the first years of life
of those patients. This may have resulted in an underestimation of
pediatric cancers. On the other hand, as a result of the awareness of a
tumor predisposition in NS among physicians, patients with NS and a
malignancy are probably more likely to be referred for PTPN11
analysis than those with NS alone. This may have resulted in an
overestimation of the life-time risk of cancer. Other constraints of our
study are its retrospective nature and the young age distribution of the
study cohort, with a median age of 13 years. Clearly, multicenter life-
long follow-up studies are required to evaluate the full spectrum of
cancer risk in NS patients with a PTPN11 mutation. Similarly, such
studies may be required to monitor the effect of growth hormone
(GH) therapy for short stature in children with NS. As GH can cause
proliferation of normal and malignant cells, the possibility that GH
can induce cancer, specifically in persons with a tumor predisposition,
has resulted in concerns over its use. Until now, however, follow-up
studies in large cohorts of children and in smaller cohorts of adults
have indicated that GH is not associated with an increased risk of
tumor occurrence or recurrence (reviewed in refs Jenkins et al45;
Ogilvy-Stuart and Gleeson46). But, as these studies have been performed
in recipients of GH therapy who do not have a cancer predisposing
genetic condition and the average duration of follow-up is only 4 years,
we still recommend that all NS patients who have received GH should
be included in follow-up programs to assess a possible relation between
cancer risk and GH therapy in this specific condition.
A surveillance program for patients with a tumor predisposition
syndrome is indicated when the benefits of such a strategy outweigh
the disadvantages. The increased risk for developing a malignancy
should be evident and early detection of cancer should positively
influence patient outcome. In this study we showed that, although
there is an increased risk of developing cancer in patients with NS with
a PTPN11 mutation, the malignancies involve multiple sites and
develop throughout life, making a straightforward screening protocol
ineffective. Moreover, for hematological malignancies, most frequently
occurring in NS, benefit of monitoring is unclear. Therefore, we
conclude that at present a tumor surveillance program is not war-
ranted for patients with NS carrying a PTPN11 mutation.
In conclusion, we have found an excess risk of cancer in patients
carrying a mutation in PTPN11, compared with the risk of cancer in
the general population. In addition to several malignancies that one
would expect in a cohort of PTPN11 mutation carriers, some cancers
were encountered that so far were not associated with NS. The
initiation and/or progression of these tumors may very well be because
of activating mutations in the PTPN11 gene. Both, on the basis of
literature data and those presented here, however, no clear correlation
has emerged between specific mutations in PTPN11 and the occur-
rence of cancer. Our data do not warrant a tumor surveillance
program for patients with NS and a mutation in PTPN11.
Table 2 Frequency of PTPN11 mutations associated with cancer in
our cohort and literature data on its somatic occurrence
PTPN11 mutation
Cancer related
frequencya
Previously reported as somatic
mutation in cancerb
c.179G4C (p.Gly60Ala) 1 of 8 +
c.188A4G (p.Tyr63Cys) 2 of 41 +
c.417G4C (p.Glu139Asp) 1 of 17 +
c.774G4T (p.Glu258Asp) 1 of 3 
c.844A4G (p.Ile282Val) 1 of 14 
c.922A4G (p.Asn308Asp) 1 of 62 
c.925A4G (p.Ile309Val) 1 of 3 
c.1472C4T (p.Pro491Leu) 1 of 4 +
c.1508G4C (p.Gly503Ala) 1 of 1 +
c.1510A4G (p.Met504Val) 2 of 17 
aThe second number represents how often the mutation has been identified in our cohort,
whereas the first number displays the number of patients in the cohort with this mutation who
developed a malignancy.
bThe data in this column are derived from Aoki et al.38
Figure 1 Age-specific cumulative risk of cancer in patients with Noonan
syndrome and a mutation in PTPN11. We found a cumulative risk of 23%
(95% CI, 7.6–38.4%) up to age of 55 years, which represents a 3.5-fold
increased risk (95% CI, 2.0–5.9) compared with the general population.
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